

# Buprenorphine Network



THURSDAY, SEPTEMBER 8, 2022

Division of Mental Health & Addiction Services  
wellnessrecoveryprevention



# Buprenorphine Network

2

A Certificate of Waiver for Medication Assisted Treatment pursuant to N.J.A.C. 8:43 issued by the Department of Health Certificate of Need and Licensing (CN&L) is required for a licensed site to provide Vivitrol and/or Buprenorphine/Suboxone.

# Buprenorphine Network

3

Effective November 1, 2022

Buprenorphine/Suboxone medication and associated services are being added to the DMHAS SUD FFS through the development of a new Enhancement package.

This change will allow licensed SUD FFS Agencies that have a MAT Waiver issued to their site, access to FFS reimbursement for these medications.



# Buprenorphine Network

4

Any site that does not have the MAT Waiver will no longer be able to be reimbursed for Vivitrol and will not be able to be reimbursed for Buprenorphine/Suboxone through DMHAS SUD FFS.

A DMHAS SUD FFS contract modification will be forwarded to each agency notifying them of any contract change.

# Buprenorphine Network

5

Once implemented in [www.nj-das.net](http://www.nj-das.net), the new Vivitrol or Buprenorphine Enhancement Packages will be available in the following initiatives:

- Driving Under the Influence Initiative (DUII)
- Medication Assisted Treatment Initiative (MATI)
- Mutual Agreement Program – State Parole Board (MAP SPB)
- New Jersey Statewide Initiative (NJSI)
- Recovery Court Initiative (RCI) formerly Drug Court Initiative
- Recovery Court Contract (RCC) formerly Drug Court Contract
- State Hospital Access to Rehabilitation and Education (SHARE)
- South Jersey Initiative (SJI)